National Bank of Canada
PMCB icon

National Bank of Canada’s PharmaCyte Biotech PMCB Stock Holding History

National Bank of Canada’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,300
Closed -$3.56K – 3142
2025
Q2 		$3.56K Hold
3,300
– – ﹤0.01% 2555
2025
Q1 		$4.09K Buy
+3,300
New +$5.35K ﹤0.01% 2410

Other funds holding PMCB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

National Bank of Canada's PMCB Position: Q3 2025 in Review

National Bank of Canada sold out of PharmaCyte Biotech (PMCB) in Q3 2025, closing a stake of 3,300 shares — an estimated $3.56K sold.

National Bank of Canada first reported a position in PMCB in Q1 2025 and held it in 2 quarters. The position peaked at $4.09K in Q1 2025. 23 funds tracked by Wall St. Rank hold PMCB as of Q3 2025.

  • National Bank of Canada reported no remaining PharmaCyte Biotech position as of Q3 2025 after selling out during the quarter.
  • National Bank of Canada sold 3,300 PharmaCyte Biotech shares in Q3 2025, an estimated $3.56K.
  • National Bank of Canada first reported a position in PharmaCyte Biotech in Q1 2025 and held it in 2 quarters.
  • National Bank of Canada's PharmaCyte Biotech position peaked at $4.09K in Q1 2025.
  • 23 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2025.

Based on National Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.